SCHEMBL187309

SCHEMBL187309

O=C(CCl)N1CC=C(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CCR2 P41597 1/20 0.48
HTR2C P28335 2/20 0.45
CNR1 P21554 1/20 0.44
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
HTR7 P34969 2/20 0.43
SOS1 Q07889 1/20 0.43
HTT P42858 2/20 0.43
POLB P06746 1/20 0.43
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1760912 0.86 CCR2 (0.50) MEN1KMT2ACCR2HTR2CPPARG
Hydrochloric Acid SCHEMBL10734951 0.85 MEN1 (0.53) MEN1KMT2ACCR2HTR2CPPARG
SCHEMBL2930491 0.85 CCR2 (0.51) MEN1KMT2ACCR2HTR2CPPARG
SCHEMBL10744551 0.83 CCR2 (0.49) MEN1KMT2ACCR2HTR2CPPARG
SCHEMBL5727281 0.83 MEN1 (0.50) MEN1KMT2AHTTPOLBLMNA
SCHEMBL10743860 0.82 CCR2 (0.48) MEN1KMT2ACCR2HTR2CPPARG
SCHEMBL10737854 0.82 CCR2 (0.48) MEN1KMT2ACCR2HTR2CPPARG
SCHEMBL27886023 0.82 MEN1 (0.71) MEN1KMT2ACNR1HTTNPC1
SCHEMBL10740033 0.82 MEN1 (0.49) MEN1KMT2ACCR2PPARGPPARA
SCHEMBL14282249 0.81 ALDH1A1 (0.51) MEN1KMT2ACCR2HTR2CPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519143-B2 Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors SANOFI (FR) 2013-08-27 US disclosed
US-20120232280-A1 DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS SANOFI-AVENTIS (FR) 2012-09-13 US disclosed
US-8193190-B2 Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors SANOFI-AVENTIS (FR) 2012-06-05 US disclosed
EP-2297148-B1 NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS SANOFI SA (FR) 2012-01-04 EP disclosed
US-20110144116-A1 DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS SANOFI-AVENTIS (FR) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144116-A1 DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS NGF, NTRK2, NTRK3 MEN1 4190/4885KMT2A 4374/4885CCR2 1084/4885
US-20120232280-A1 DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS NGF, NTRK2, NTRK3 MEN1 4190/4885KMT2A 4374/4885CCR2 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.